Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Debt Repayments (2021 - 2022)

ARS Pharmaceuticals' Long-Term Debt Repayments history spans 2 years, with the latest figure at $6.0 million for Q4 2022.

  • For Q4 2022, Long-Term Debt Repayments rose 513.18% year-over-year to $6.0 million; the TTM value through Sep 2023 reached $6.0 million, up 61.01%, while the annual FY2022 figure was $8.7 million, 377.77% up from the prior year.
  • Long-Term Debt Repayments for Q4 2022 was $6.0 million at ARS Pharmaceuticals, up from $909000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $6.0 million in Q4 2022 and bottomed at $350000.0 in Q1 2021.